Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
VALTREX (valacyclovir HCl) is an oral antiviral small molecule approved in 1995 for treatment of herpes simplex, herpes zoster, genital herpes, cytomegalovirus infections, and chickenpox. It is a prodrug that is converted to acyclovir, inhibiting viral DNA polymerase to prevent viral replication. The drug is administered orally as tablets, making it convenient for outpatient management of herpesvirus infections.
Product is in late-stage lifecycle with modest Part D spending, signaling potential consolidation or deprioritization of brand-specific roles within GSK's antiviral franchise.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)
Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
Worked on VALTREX at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moVALTREX appears to have minimal active job postings linked to this product, reflecting its mature market status and generic competition. Career opportunities on this product are likely limited to support roles, field-based positions, or transition assignments within GSK's broader antiviral portfolio.